Secondary Logo

GERSHENSON DAVID M. MD; KAVANAGH, JOHN J. MD; COPELAND, LARRY J. MD; STRINGER, C ALLEN MD; MORRIS, MITCHELL MD; WHARTON, J TAYLOR MD
Obstetrics & Gynecology: May 1989
Original Article: PDF Only
Free

Nineteen patients with recurrent epithelial ovarian cancer who had responded to initial cisplatin-based combination chemotherapy were re-treated with cisplatin-based therapy. The median disease-free interval, as measured from the last cycle of primary chemotherapy to the diagnosis of relapse, was 26.3 months (range 5–81 months). Eighteen of the 19 patients had measurable disease at the time of relapse. Nine patients had a clinical complete response to the cisplatin-based re-treatment, and nine patients had a partial response (surgically documented in one case). The overall response rate to secondary cisplatin-based chemotherapy was therefore 100% in patients with measurable disease. Toxicity of re-treatment was acceptable. The median progression-free survival, as measured from the diagnosis of relapse to the time of disease progression, was 10.6 months (range 4–24 months). The median survival from diagnosis of relapse was 19.3 months (range 5–39 months). At the time of analysis, three patients were alive without evidence of disease, four were alive with tumor, and 12 were dead of cancer. These data suggest that re-induction with cisplatin-based chemotherapy should be considered for patients who develop recurrent disease after favorable responses to primary cisplatin-based chemotherapy.

© 1989 The American College of Obstetricians and Gynecologists